Profile of:

Augusta Ortolan


Augusta Ortolan is a rheumatologist and researcher at Università Cattolica del Sacro Cuore – Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy. She trained in rheumatology and earned her PhD at the University of Padova, and she holds an MSc in Epidemiology from Maastricht University. In 2017 she was a clinical research fellow at Leiden University Medical Center, working on the SPACE cohort. Her research focuses on outcome measurement and clinimetrics in axial spondyloarthritis and psoriatic arthritis. Her work includes the development of an alternative ASDAS and the longitudinal determinants of health-related quality of life. She was a fellow of the 2022 ASAS-EULAR recommendations task force and served on the steering committee of the ASAS-SPARADISE project. She has been an ASAS full member since 2024 and has authored over 90 peer-reviewed publications.

Full name: Augusta Ortolan

Current country: Italy

Membership level: Full

Type of membership: Member

Number of publications: 13

Peripheral manifestations in spondyloarthritis: a systematic literature review on their assessment and the effect of biological/targeted synthetic DMARDs (2026)
https://pubmed.ncbi.nlm.nih.gov/41666292/

Final validation of the hierarchical framework for outcomes in axial spondyloarthritis: longitudinal determinants of health-related quality of life. (2026)
https://pubmed.ncbi.nlm.nih.gov/41238490/

The impact of diet on disease activity in spondyloarthritis: A systematic literature review (2023)
https://pubmed.ncbi.nlm.nih.gov/36404571/

External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomized clinical trials of ixekizumab (2023)
https://pubmed.ncbi.nlm.nih.gov/36282526/

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. (2023)
https://pubmed.ncbi.nlm.nih.gov/36270658/

Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. (2023)
https://pubmed.ncbi.nlm.nih.gov/36270657/

Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis (2023)
https://pubmed.ncbi.nlm.nih.gov/36261247/

Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. (2022)
https://pubmed.ncbi.nlm.nih.gov/35510168/

Psoriasis and imaging progression in early axial spondyloarthritis: results from a 48-month follow-up (Italian arm of SPACE study) (2022)
https://pubmed.ncbi.nlm.nih.gov/34605894/

Mediterranean diet in axial spondyloarthritis: an observational study in an Italian monocentric cohort (2021)
https://pubmed.ncbi.nlm.nih.gov/34416917/

The Genetic Contribution to Drug Response in Spondyloarthritis: A Systematic Literature Review (2021)
https://pubmed.ncbi.nlm.nih.gov/34354741/

Do we believe in non-radiographic axial spondyloarthritis? A debate. (2021)
https://pubmed.ncbi.nlm.nih.gov/33188919/

Do we believe in non-radiographic axial spondyloarthritis? A debate. (2021)
https://pubmed.ncbi.nlm.nih.gov/33188919/